Filing Details
- Accession Number:
- 0001562180-23-004067
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-11 13:53:12
- Reporting Period:
- 2023-05-09
- Accepted Time:
- 2023-05-11 13:53:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 105770 | West Pharmaceutical Services Inc | WST | Surgical & Medical Instruments & Apparatus (3841) | 231210010 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1336007 | Mark Eric Green | 530 Herman O. West Drive Exton PA 19341 | President & Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-09 | 50,000 | $57.38 | 178,574 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-09 | 14,157 | $361.95 | 164,417 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-05-09 | 12,562 | $362.93 | 151,855 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-05-09 | 12,648 | $363.94 | 139,207 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-05-09 | 4,133 | $364.76 | 135,074 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-05-09 | 500 | $365.46 | 134,574 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-05-09 | 50,000 | $0.00 | 50,000 | $57.38 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 148,132 | 2025-04-24 | No | 4 | M | Direct |
Footnotes
- The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022.
- This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $361.42 to $362.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $362.42 to $363.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $363.42 to $364.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $364.425 to $365.295, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $365.43 to $365.48, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
- This option is fully vested.
Billionaire Hedge Funds
